Properties of CD8 T-cell-recognized neoantigens in different tumor types
Steven L. C. Ketelaars(The Netherlands Cancer Institute), John B.A.G. Haanen(Leiden University Medical Center), Marit M. van Buuren(The Netherlands Cancer Institute), Anastasia Gangaev(The Netherlands Cancer Institute), Kelly Hoefakker(The Netherlands Cancer Institute), Lorenzo F. Fanchi(The Netherlands Cancer Institute), S Patiwael(The Netherlands Cancer Institute), Nienke van Rooij(The Netherlands Cancer Institute), Marleen Kok(The Netherlands Cancer Institute), Ton N. Schumacher(Leiden University Medical Center), M. van der Heijden(The Netherlands Cancer Institute), Pia Kvistborg(The Netherlands Cancer Institute)
Cited by 2
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
|The Lancet Oncology|2014|978
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
|Journal of Clinical Oncology|2013|799
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
|Nature|2017|697